Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-03-11 Annual Report
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis 2024 Consolidated IFRS Financial Statements.pdf
Annual Report Classification · 100% confidence The document contains the full consolidated financial statements of Oculis Holding AG, including the Report of the Independent Registered Public Accounting Firm, Consolidated Statements of Financial Position, Loss, Comprehensive Loss, Changes in Equity, and Cash Flows for the years ended 2024, 2023, and 2022. It includes detailed notes to the financial statements. This is a comprehensive annual financial report, which fits the definition of a 10-K (Annual Report). FY 2024
2025-03-11 English
Oculis 2024 MDA.pdf
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Oculis, covering company overview, business environment, financial performance, and detailed operational results for the fiscal year ended December 31, 2024. It includes specific financial data, management's discussion of operations, and details on capital structure and financing. Given the length and the inclusion of substantive financial and operational analysis, it is classified as an Annual Report (10-K). FY 2024
2025-03-11 English
Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins
Earnings Release Classification · 95% confidence The document is a press release from Oculis Holding AG announcing their financial results for the fourth quarter and the full year 2024. It includes key operational highlights, financial summaries, and consolidated financial statements (Balance Sheet and Statement of Loss). While it contains financial data, it is structured as an initial earnings announcement (Earnings Release) rather than a full 10-K annual report, as indicated by the 'GLOBE NEWSWIRE' header and the summary-style presentation of highlights followed by detailed tables. Q4 2024
2025-03-11 Icelandic
Oculis 2024 Consolidated IFRS Financial Statements.pdf
Annual Report Classification · 100% confidence The document contains the full set of consolidated financial statements (Statements of Financial Position, Loss, Comprehensive Loss, Changes in Equity, and Cash Flows) for Oculis Holding AG for the years ended December 31, 2024, 2023, and 2022, along with the Report of the Independent Registered Public Accounting Firm. This constitutes a comprehensive annual financial report, which is classified as a 10-K. FY 2024
2025-03-11 English
Oculis ESEF reporting.zip
Annual Report (ESEF) Classification · 100% confidence FY 2023
2025-03-11 English
Oculis Q4 2024 - Press Release.pdf
Earnings Release Classification · 100% confidence The document is a press release from Oculis titled 'Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update'. It contains key financial highlights, operational updates, and condensed financial statements (Consolidated Statements of Financial Position and Loss). While it includes financial data, it is structured as an initial announcement of quarterly and annual results rather than a full 10-K or a comprehensive interim report. According to the filing definitions, this fits the 'Earnings Release' (ER) category, as it provides the initial summary of financial performance and business highlights for the period. FY 2024
2025-03-11 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.